Skip to main content

Private equity

Sofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap

Monday, November 16, 2026 · first reported by AltAssets and 2 others

Sofinnova Partners has closed Sofinnova Crossover II at €725 million ($815 million per HedgeCo), above its original target. AltAssets puts the fund at 63% larger than its predecessor.

The vehicle will hold about 15 companies, mainly European clinical-stage biopharma and medtech businesses needing capital to reach commercialization, with some investments in the United States and elsewhere. Partner Kinam Hong said about 80% will go to Europe. Investing has begun, with Neurent Medical, Hemab Therapeutics and CellCentric among the first holdings.

Size
€725M (≈$789M)
Stage
Target
Asset class
Private equity, Venture
Geography
Europe

In the data This close in the fund closes table · Every Sofinnova Partners close

The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.

See an error?

Coverage

3 sources

Got news? Send it to us →